Therapy Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Therapy Name Tulmimetostat
Synonyms
Therapy Description

Tulmimetostat is a second-generation inhibitor of EZH1 and EZH2, which potentially decreases tumor cell viability and reduces tumor growth (PMID: 38833522).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Tulmimetostat CPI0209|CPI-0209|CPI 0209|DZR123|DZR-123|DZR 123 EZH1 inhibitor 5 EZH2 inhibitor 20 Tulmimetostat is a second-generation inhibitor of EZH1 and EZH2, which potentially decreases tumor cell viability and reduces tumor growth (PMID: 38833522).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
ARID1A G1450fs urinary bladder cancer sensitive Tulmimetostat Preclinical - Cell culture Actionable In a preclinical study, Tulmimetostat inhibited viability in 5/6 bladder cancer cell lines harboring ARID1A loss of function mutations including ARID1A G1450fs in culture (PMID: 38833522). 38833522
ARID1A S552* urinary bladder cancer sensitive Tulmimetostat Preclinical - Cell culture Actionable In a preclinical study, Tulmimetostat inhibited viability in 5/6 bladder cancer cell lines harboring ARID1A loss of function mutations including ARID1A S552* in culture (PMID: 38833522). 38833522
ARID1A inact mut endometrial cancer sensitive Tulmimetostat Preclinical - Pdx Actionable In a preclinical study, Tulmimetostat inhibited tumor growth in endometrial cancer patient-derived xenograft (PDX) models harboring loss of function mutations in ARID1A (PMID: 38833522). 38833522
ARID1A P549fs ARID1A N756fs ovarian clear cell carcinoma sensitive Tulmimetostat Preclinical - Cell line xenograft Actionable In a preclinical study, Tulmimetostat inhibited viability of an ovarian clear cell carcinoma cell line harboring ARID1A N756fs and P549fs in culture and inhibited tumor growth in a cell line xenograft model (PMID: 38833522). 38833522
ARID1A inact mut urinary bladder cancer sensitive Tulmimetostat Preclinical - Pdx Actionable In a preclinical study, Tulmimetostat inhibited tumor growth in a bladder cancer patient-derived xenograft (PDX) model harboring a loss of function mutation in ARID1A (PMID: 38833522). 38833522
ARID1A S2256* urinary bladder cancer sensitive Tulmimetostat Preclinical - Cell culture Actionable In a preclinical study, Tulmimetostat inhibited viability in 5/6 bladder cancer cell lines harboring ARID1A loss of function mutations including ARID1A S2256* in culture (PMID: 38833522). 38833522

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT05944562 Phase I Tulmimetostat Tulmimetostat (CPI-0209) in Patients With Mycosis Fungoides and Sezary Syndrome Recruiting USA 0
NCT04104776 Phase Ib/II Enzalutamide + Tulmimetostat Tulmimetostat A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas Recruiting USA | POL | ITA | GBR | FRA | ESP 1


Additional content available in Icon for CKB-BoostCKB BOOST